You are viewing the site in preview mode

Skip to main content

Table 2 Main characteristics of eligible studies for diagnosis

From: Circulating long noncoding RNAs as potential biomarkers for stomach cancer: a systematic review and meta-analysis

First author, year Race Pathologictype (E/C) Sample size (E/C) Specimen lncRNA State Sen Spe TP FP FN TN QUADAS-2 (Refs)
Liu, 2019 Asian GC/HD 89/73 Serum FEZF1-AS1 Up 75.3% 65.8% 67 25 22 48 5 [15]
     AFAP1-AS1 Up 76.4% 56.2% 68 32 21 41   
Yoruke, 2018 Caucasian GC/non-GC 40/42 Plasma H19 Up 87.2% 38.1% 35 26 5 16 6 [16]
Liu, 2019 Asian GC/HD 100/100 Serum MALAT1 Up 85.8% 74.5% 86 26 14 75 4 [17]
Hashad, 2016 Caucasian GC/HD 32/30 Plasma H19 Up 68.8% 56.7% 22 13 10 17 5 [18]
Li, 2014 Asian GC/HD 79/81 Plasma exosome LINC00152 Down 48.1% 85.2% 38 12 41 69 6 [19]
Liu, 2014 Asian GC/HD 83/80 Plasma FER1L4 Up 67.2% 80.3% 56 16 27 64 7 [20]
Liu, 2018 Asian GC/HD 50/50 Plasma CTC-501O10.1 Up 90.0% 51.0% 45 25 5 26 6 [21]
     AC100830.4 Up 84.0% 58.0% 42 21 8 29   
     RP11-210K20.5 Up 89.0% 55.0% 45 23 6 28   
Lu, 2017 Asian EGC/HD 76/76 Serum XIST Up 84.6% 59.0% 64 31 12 45 5 [22]
     BCYRN1 Up 67.9% 85.9% 52 11 24 65   
     RRP1B Down 85.9% 56.4% 65 33 11 43   
     TDRG1 Down 73.1% 60.3% 56 30 20 46   
Mohamed, 2019 Caucasian GC/HD 35/25 Serum H19 Up 90.9% 100.0% 32 0 3 25 5 [23]
Piao, 2020 Asian GC/HD 281/80 Plasma exosome CEBPA-AS1 Up 74.0% 88.0% 208 10 73 70 6 [24]
Zhou, 2016 Asian GC/HD 77/60 Plasma ZFAS1 Up 76.6% 63.9% 59 22 18 38 5 [25]
Cai, 2019 Asian GC/HD 63/29 Serum exosome PCSK2-2:1 Up 84.0% 86.5% 53 4 10 25 6 [26]
Zhou, 2015 Asian GC/HD 90/90 Plasma H19 Up 82.9% 72.9% 75 24 15 66 7 [27]
Elsayed, 2018 Caucasian GC/HD 50/50 Plasma HOTAIR Up 86.0% 94.0% 43 3 7 47 4 [28]
Xian, 2018 Asian GC/HD 50/50 Plasma HULC Up 58.0% 80.0% 29 10 21 40 5 [29]
     ZNFX1-AS1 Up 84.0% 68.0% 42 16 8 34   
Feng, 2019 Asian GC/HD 107/87 Serum B3GALT5-AS1 Up 64.5% 87.4% 69 11 38 76 5 [30]
Fu, 2017 Asian GC/HD 72/72 Serum LINC00978 Up 80.0% 70.0% 58 22 14 50 5 [31]
Gao, 2015 Asian GC/HD 20/20 Plasma UCA1 Up 85.0% 96.3% 17 1 3 19 6 [32]
     PVT1 Down 70.8% 91.3% 14 2 6 18   
Ghaedi, 2018 Asian GC/HD 62/40 Plasma H19 Up 74.2% 90.0% 46 4 16 36 6 [33]
     MEG3 Down 77.4% 52.5% 48 19 14 21   
Guo, 2020 Asian EGC/HD 217/219 Plasma exosome GC1 Up 97.0% 83.0% 210 37 7 182 5 [34]
Arita, 2013 Asian GC/HD 43/34 Plasma H19 Up 74.0% 58.0% 32 14 11 20 6 [35]
Ji, 2019 Asian GC/HD 168/74 Plasma LINC00086 Down 72.6% 83.8% 122 12 46 62 7 [36]
Jiang, 2019 Asian GC/HD 317/100 Plasma PCGEM1 Up 72.9% 88.9% 231 11 86 89 7 [7]
Lin, 2018 Asian GC/HD 51/60 Plasma exosome UEGC1 Up 88.0% 82.0% 45 11 6 49 5 [37]
     UEGC2 Up 89.0% 58.0% 45 25 6 35   
Pan, 2017 Asian GC/HD 60/37 Serum exosome ZFAS1 Up 71.7% 75.7% 43 9 17 28 5 [38]
Jin, 2016 Asian GC/HD 173/110 Serum HULC Up 82.0% 83.6% 142 18 31 92 6 [39]
Zhang, 2018 Asian GC/HD 57/29 Serum exosome UFC1 Up 78.0% 80.0% 44 6 13 23 5 [2]
Zhao, 2018 Asian GC/HD 126/120 Serum exosome HOTTIP Up 69.8% 85.0% 88 18 38 102 4 [40]
Burock, 2015 Caucasian GC/non-GC 76/54 Plasma MACC1 Up 68.0% 89.0% 52 6 24 48 5 [41]
Ke, 2017 Asian GC/HD 51/53 Plasma INHBAAS1 Down 92.7% 74.5% 47 14 4 39 6 [42]
     MIR4435-2HG Down 90.2% 74.5% 46 14 5 39   
     CEBPA-AS1 Down 78.0% 76.6% 40 12 11 41   
     UCA1 Down 73.2% 82.3% 37 9 14 44   
     AK001058 Down 95.1% 72.3% 49 15 2 38   
   47/52 Plasma INHBAAS1 Down 82.7% 59.6% 39 21 8 31   
     MIR4435-2HG Down 65.4% 87.2% 31 7 16 45   
     CEBPA-AS1 Down 96.2% 57.4% 45 22 2 30   
     AK001058 Down 76.9% 92.3% 36 4 11 48   
Liu, 2019 Asian GC/HD 94/40 Serum HOXA11-AS Up 78.7% 97.8% 74 1 20 39 7 [43]
Shan, 2019 Asian GC/HD 117/100 Serum UCA1 Up 93.2% 78.6% 109 21 8 79 6 [44]
Shao, 2016 Asian GC/HD 83/90 Plasma RMRP Down 59.1% 67.8% 49 29 34 61 5 [45]
Yang, 2019 Asian GC/HD 109/106 Plasma FOXD2-AS1 Up 83.0% 50.0% 90 53 19 53 5 [46]
     PANDAR Up 85.0% 63.0% 93 39 16 67   
     SMARCC2 Up 90.0% 55.0% 98 48 11 58   
Xu, 2020 Asian GC/HD 109/50 Serum MIAT Up 81.5% 87.5% 89 6 20 44 5 [47]
Xu, 2018 Asian GC/HD 34/34 Plasma DGCR5 Down 58.0% 87.0% 20 4 14 30 6 [48]
Xu, 2019 Asian GC/HD 45/45 Plasma LINC01225 Up 50.0% 90.0% 23 5 23 41 4 [49]
Yang, 2016 Asian GC/HD+GS 133/152 Serum H19 Up 65.0% 53.0% 86 71 47 81 7 [50]
     LINC00152 Up 40.0% 72.0% 53 43 80 109   
Zheng, 2020 Asian GC/HD 60/60 Plasma SLC2A12-10:1 Up 68.0% 75.0% 41 15 19 45 5 [51]
Zheng, 2018 Asian GC/HD 241/228 Plasma FAM49B-AS Up 58.0% 60.0% 140 91 101 137 6 [52]
     GUSBP11 Up 46.0% 75.0% 111 57 130 171   
     CTDHUT Up 73.0% 65.0% 176 80 65 148   
Zhou, 2020 Asian GC/GS+GA+GD 200/278 Serum C5orf66-AS1 Down 77.5% 53.6% 155 129 45 149 6 [53]
Tan, 2016 Asian GC/HD 117/80 Plasma GACAT2 Down 87.2% 28.2% 102 57 15 23 5 [54]
  1. E/C experimental group/control group, GC gastric cancer, EGC early gastric cancer, HD healthy donor individuals, GS superficial gastritis, GA atrophic gastritis, GD gastric dysplasia, SEN sensitivity, SPE specificity, TP true positive, FP false positive, FN false negative, TN true negative, QUADAS-2 Quality Assessment of Diagnostic Accuracy Studies 2
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us

\